The Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia
Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
Fibromyalgia (FM) is a chronic pain syndrome characterized by widespread pain, fatigue, and emotional disorders. Its onset is related to factors such as central sensitization and imbalance of neurotransmitters. The current mainstream treatments include pregabalin, but the efficacy of pregabalin is limited, with only 25%-40% pain relief rate, and adverse reactions are common. Dexmedetomidine, a highly selective 2-adrenergic receptors agonist, could improve sleep disorders, making it a possible treatment option for treating FM. We hypothesize that the combination of pregabalin with dexmedetomidine may offer greater pain relief compared pregabalin monotherapy, without a significant increase in adverse effects for patients with FM.